image description
CARE PATHWAY intelligence SOLUTIONs

Tempus Next Cardiology

AI-enabled care pathway platform to help clinicians find patients with undiagnosed or undertreated cardiovascular or pulmonary disease. Tempus Next ingests multimodal data, runs AI-based algorithms, and surfaces insights for care teams to evaluate and action on.

Improve adherence to clinical guidelines through AI-enabled and targeted notification at the point of care for diagnostic and treatment decision support.

image description image description

UPCOMING WEBINAR

AI Algorithms in Cardiology: Streamlining the Path from Research to Practice

Learn more about how Tempus is developing ECG AI algorithms to revolutionize cardiology from development to clinical utility in our comprehensive webinar.

Register for our webinar

Our PARTNERSHIPS

Accelerating cardiac therapy breakthroughs with AI through algorithm development, validation and scaled clinical adoption

We develop algorithms in partnership with an industry leader to identify patients at risk of undiagnosed disease.

Tempus can lead multi-site studies of investigational AI-based cardiology algorithms, and facilitate these studies using our Tempus Next software. We can support evaluation of clinical use and timely clinical detection of cardiac events, and track clinical outcomes. These studies can provide evidence to support development, publication, regulatory, reimbursement and clinical adoption goals.

The algorithm is investigational, has not received approval or clearance from the U.S. Food and Drug Administration, and at this time is not available for clinical use.

Read more
image description

We bring AI based algorithms through FDA clearance.

With deep regulatory experience, we are expanding our algorithms across 15+ disease areas in cardiology.

We are pursuing development and clearance of AI-based cardiology algorithms as “cardiovascular machine learning-based notification software”. These algorithms can analyze physiological inputs using machine learning models, and suggest the likelihood of a cardiovascular disease or condition for further referral or diagnostic follow-up.

Read more
image description

We deploy algorithms across our network.

Tempus care gap algorithms help find undiagnosed or undertreated disease and close gaps in care at scale.

  • 350+ EHR connected health systems across 2,000+ hospitals
  • 100+ hospitals nationwide are currently powered by Tempus Next
image description

We increase equitable access to cardiology care and reduce disparities.

Tempus is committed to the mission of providing timely and accurate diagnostics, procedures and therapies for all patients, regardless of socioeconomic status.

Figure: In this study, black patients saw a larger decrease in average time from index echo to follow up (120 vs 64 days) compared to white patients (57 to 36 days), showing the improvement in black patients’ time to follow up towards the average seen in white patients’ (narrowing the gap).

Horde G, Sotelo M, D’Amico A, et al. Use of an echocardiographic-based, artificial intelligence system to improve racial disparities in care of patients with valvular heart disease. European Heart Journal – Cardiovascular Imaging. 2023;24(Suppl 1):38.3.

image description

Our impact ON PATIENT CARE

  • 60+

    algorithms to identify potential care gaps across 15 cardiovascular diseases

  • ~2M

    patients screened

  • 50K+

    patients screened per month

image description

Case Study

Identifying patients with valvular heart disease: A partnership between St. Francis and Tempus

Learn how the deployment of Tempus Next, an AI-enabled clinical care pathway solution, at a specialty designated cardiac and heart valve center helped enable guideline directed care for patients with structural heart disease.

LEARN MORE
image description

Case Study

Revolutionizing Cardiac Care: AI-Driven Detection and Treatment of Critical Heart Valve Disease at Boulder Community Health

Discover how Tempus Next’s AI-powered care pathway platform transformed patient outcomes by helping ensure timely, guideline-directed treatment for critical heart valve disease at Boulder Community Health.

LEARN MORE
image description

Predictive Algorithms for Undiagnosed Disease

image description image description

Disease areas

AORTA

Tempus Next includes screening algorithms for abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) using clinician reports from abdominal ultrasounds and CTs, in addition to all other available patient data. Our system provides guidelines driven notifications and follows patients through progression from low severity to high severity.

Structural heart

Tempus Next Structural Heart capabilities include screening for appropriate care across aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonary regurgitation. Tempus Next delivers guidelines driven notifications to help providers close care gaps in these populations.

Case Study: Identifying patients with Valvular Heart Disease: A partnership between St. Francis and Tempus

Learn how the deployment of Tempus Next, an AI-enabled clinical care pathway solution, at a specialty designated cardiac and heart valve center helped enable guideline directed care for patients with structural heart disease.

Read more

Cardiomyopathies

Within cardiomyopathies, Tempus Next screening protocols address care across non-ischemic dilated cardiomyopathy and cardiac oncologic disease. Our mission is to shorten the time to referral for consideration of advanced heart failure treatment options like left ventricular assist devices or heart transplants. We also aim to enable clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists based on guidelines.

Electrophysiology

Tempus Next electrophysiology capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States; however, prevention is challenging due to difficulty identifying at-risk patients.1 Less than 10% of patients who meet the AHA/ACC/HRS guidelines criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device, with women more likely to be undertreated.2 Tempus Next continuously monitors patient data to find at-risk patients, and alerts the patient’s care team of any guidelines based follow-up or disease progression.

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF).4

Read more

Guideline Directed Medical Therapies

Tempus Next screens for an array of additional conditions including congestive heart failure and ischemic heart diseases. Our program monitors length of time and patient adherence to Guideline Directed Medical Therapy, as well as key markers including ejection fraction during this period to determine the potential need for referral to a heart clinic based on guidelines. Studies have shown that patients not optimized on Guideline Directed Medical Therapy are 26% more likely to have higher annualized healthcare utilization and emergency department visits.3

Pulmonary Hypertension

Tempus is sponsoring a multi-site study of an investigational AI algorithm that analyzes the results of a 12-lead electrocardiogram (ECG) to find patients at increased risk of having undetected pulmonary hypertension (PH). Clinicians will evaluate the AI’s ability to detect patients at risk of undiagnosed PH, and will track clinical outcomes of patients who are identified for further evaluation. The study will leverage Tempus Next, our care pathway intelligence solution, to facilitate the PH algorithm’s investigational use at participating institutions.

Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies.

Read more

Featured News

view all news
  • UPCOMING WEBINAR:

    Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF).

    Read more
  • UPCOMING WEBINAR:

    Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies.

    Read more

Our Science

view all
  • UPCOMING WEBINAR:

    A Novel Phenotyping Pipeline to Improve Identification of Patients with Pulmonary Hypertension in Electronic Health Records

    05/22/2024

    Read more
  • UPCOMING WEBINAR:

    ECG-based Machine Learning Model Identifies Patients at High Risk for Incident Pulmonary Hypertension

    05/22/2024

    Read more
  • UPCOMING WEBINAR:

    Structured EHR Data Underestimates Prevalence and Misses Large Proportions of Patients with Pulmonary Hypertension

    05/22/2024

    Read more
  • UPCOMING WEBINAR:

    Predictors of Disease Progression and Adverse Clinical Outcomes in Patients With Moderate Aortic Stenosis Using an Artificial Intelligence-Based Software Platform

    05/22/2024

    Read more
  • UPCOMING WEBINAR:

    Large Language Models with Retrieval-Augmented Generation for Zero-Shot Disease Phenotyping

    12/11/2023

    Read more
  • UPCOMING WEBINAR:

    Prospective evidence generation via ECG-AID Study

    Read more
  1. Sudden Cardiac Arrest Foundation. January 29, 2020. Latest statistics: 1,000 people suffer sudden cardiac arrest each day in U.S.; only 10% survive [online]. Available from: https://www.sca-aware.org/sca-news/latest-statistics-1000-people-suffer-sudden-cardiac-arrest-each-day-in-us-only-10-survive [Accessed May 1, 2023]
  2. Husband G.; D”amico A.; Hasnie U.; Batra N.; Cochrun S.; Gann A.; Li E.; Nguyen D.; Philip George A.; Soto M.; Rogers C.; Ahmed M.; Andrikopoulou E.; UAB Hospital, Birmingham, United States of America; University of South Alabama, Mobile, United States of America; The Johns Hopkins Hospital, Baltimore, United States of America. February 2022. European Heart Journal – Cardiovascular Imaging, Volume 23, Issue Supplement_1 [online]. Available from: https://academic.oup.com/ehjcimaging/article/23/Supplement_1/jeab289.244/6522478
  3. J Comp Eff Res. October 2021. Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/34225473/ [Accessed May 1, 2023]
  4. INDICATIONS FOR USE: Tempus ECG-AF is intended for use to analyze recordings of 12-lead ECG devices and detect signs associated with a patient experiencing atrial fibrillation and/or atrial flutter (collectively referred to as AF) within the next 12 months. It is for use on resting 12-lead ECG recordings collected at a healthcare facility from patients: 65 years of age or older, without pre-existing or concurrent documentation of atrial fibrillation and/or atrial flutter, who do not have a pacemaker or implantable cardioverter defibrillator, and who did not have cardiac surgery within the preceding 30 days. Performance of repeated testing of the same patient over time has not been evaluated and results SHOULD NOT be used for patient monitoring. Tempus ECG-AF only analyzes ECG data. Results should be interpreted in conjunction with other diagnostic information, including the patient’s original ECG recordings and other tests, as well as the patient’s symptoms and clinical history. Tempus ECG-AF is not for use in patients with a history of AF, unless the AF occurred after a cardiac surgery procedure and resolved within 30 days of the procedure. It is not for use to assess risk of occurrence of AF related to cardiac surgery. Results do not describe a person’s overall risk of experiencing AF or serve as the sole basis for diagnosis of AF, and should not be used as the basis for treatment of AF. Results are not intended to rule-out AF or the need for follow-up.

Partner with us

We believe that AI-enabled solutions can improve the lives and outcomes of patients with cardiovascular disease. Learn more about co-developing and deploying algorithms with Tempus.